Regeneron Seeks Expedited Trial for Aflibercept Biosimilar

Share this
Regeneron Seeks Expedited Trial for Aflibercept Biosimilar

Regeneron Seeks Expedited Trial for Aflibercept Biosimilar


  • In Aug 2022, Regeneron filed a BPCIA complaint against Mylan in West Virginia alleging infringement of 24 patents related to Eylea (aflibercept). Regeneron filed a motion just two days after submitting its complaint asking for an expedited status conference and a trial date no later than June 2023
  • Regeneron is requesting a quick trial of only 10mos. after bringing its complaint to benefit from the statutory permanent injunction provided by 35 U.S.C. 271(e)(4) (D)
  • Regeneron may submit a motion for preliminary injunction based on a finding of potential infringement of a valid patent and evaluation of the standard criteria for an injunction filed within 180 days of Mylan's notification of commercial marketing

Ref: Big Molecule Watch | Image: Regeneron

Click here to­ read the full press release 


Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions